Inimmune logo

Inimmune

Harnessing the immune system to create next generation immunotherapeutics for the treatment of a wide array of diseases.

37 employees · est. 2016 · Missoula, United States

VS
TrianecT logo

TrianecT

Getting stroke patients to the right hospital for the right treatment as fast as possible.

6 employees · est. 2022 · Utrecht, The Netherlands

Inimmune is the older company (2016 vs 2022); Inimmune is the larger of the two.

Side-by-Side Comparison

Inimmune TrianecT
Founded
2016 older 2022
Headquarters
Missoula, United States Utrecht, The Netherlands
Employees
37 larger 6
Industry
Biotechnology, Health Care Health Care, Medical Devices
Funding Stage
Series A Not tracked yet
Total Funding
$22.60M Not tracked yet
Funding Rounds
3 Not tracked yet
Services
Development of disease-modifying immunotherapies, Innovative vaccine adjuvants, Clinical-stage trials for immunotherapy and vaccines, Collaborative research projects with universities and biotech firms Not tracked yet
Target Customers
Patients with allergic rhinitis, Healthcare providers focusing on immunotherapy, Biopharmaceutical companies, Research institutions and universities Not tracked yet
Taxonomy
Immunotherapeutics, Innate Immunity, Pharmaceuticals, Drug Discovery, Medical Research, Cancer Treatment, Autoimmune Diseases, Allergy Treatment, Medical Technology, Biopharmaceuticals Medical Technology, Stroke Treatment, Emergency Medical Services, Neurological Diagnostics, Healthcare Innovation, Brain Activity Measurement, Ambulance Technology, Endovascular Treatment, Emergency Response, Medical Device Development
Website
inimmune.com trianect.com
Inimmune logo

About Inimmune

Inimmune, a pioneering biotechnology startup, is making significant strides in the field of healthcare. Founded in 2016 by veterans of the pharmaceutical industry, the company is dedicated to developing next-generation immunotherapeutics designed to harness the immune system for treating a wide arra...

TrianecT logo

About TrianecT

TrianecT is a startup with a mission to get stroke patients to the right hospital for the right treatment as fast as possible. With 10 million severe stroke patients picked up by ambulances annually, the company aims to address the issue of these patients being brought to hospitals that do not have...

We will tell you when either one moves

BounceWatch watches Inimmune and TrianecT for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Inimmune and TrianecT — by email.

Frequently Asked Questions

Inimmune — Harnessing the immune system to create next generation immunotherapeutics for the treatment of a wide array of diseases.. TrianecT — Getting stroke patients to the right hospital for the right treatment as fast as possible.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Inimmune has raised $22.60M while TrianecT has raised undisclosed funding.
Inimmune and TrianecT operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Inimmune with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Inimmune on 12 Sep 2024, and TrianecT on 3 Dec 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy